Werewolf Therapeutics
Logotype for Werewolf Therapeutics Inc

Werewolf Therapeutics (HOWL) investor relations material

Werewolf Therapeutics Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Werewolf Therapeutics Inc
Q3 2026 earnings summary13 Nov, 2026

Executive summary

  • Strategic review produced the pending Ambros merger, a proposed $150.0M concurrent PIPE, and sales of the JZP898 program to Jazz and platform assets to EMD; ongoing operations depend on timely merger completion.

  • The WTX-124 and WTX-330 Phase 1/1b and Phase 1b/2 trials were completed in Q4 2026; further development requires additional funding, and strategic partnerships are being sought.

Financial highlights

  • Q3 2026 net loss was $9.9M, or $0.20/share, vs. $16.4M, or $0.36/share, in Q3 2025; 9M net loss was $19.7M vs. $52.4M.

  • 9M revenue was $21.0M from the Jazz asset sale vs. zero in 9M 2025; Q3 revenue was not listed in the operating statement.

  • Q3 R&D fell to $2.2M from $11.6M, while G&A rose to $7.9M from $4.1M, primarily reflecting lower trial and personnel costs and higher strategic transaction fees.

  • Cash and cash equivalents were $41.9M at Sept. 30, 2026 vs. $57.1M at Dec. 31, 2025; accumulated deficit was $495.1M.

Outlook and guidance

  • Near-term costs are expected to decline with workforce reductions, trial completions and other savings; resuming trial enrollment or preclinical work would increase R&D and G&A costs.

  • Existing cash is insufficient for the current operating plan through 12 months from issuance; continued operations depend on the merger or additional liquidity.

  • Further WTX-124 and WTX-330 development needs additional funding; expense levels and future plans depend on the merger outcome and strategic review.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Werewolf Therapeutics earnings date

Logotype for Werewolf Therapeutics Inc
Q4 202625 Mar, 2027
Werewolf Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Werewolf Therapeutics earnings date

Logotype for Werewolf Therapeutics Inc
Q4 202625 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Werewolf Therapeutics Inc. is a biopharmaceutical company focused on developing immunotherapies for cancer. The company specializes in engineered cytokine therapies designed to activate the immune system selectively within the tumor microenvironment. Its research and development efforts aim to enhance the efficacy and safety of immuno-oncology treatments through protein engineering and targeted delivery mechanisms. The company is headquartered in Watertown, Massachusetts, and its shares are listed on the NASDAQ.